Thank you, Mr. Chair.
To the panel members, I'd like your thoughts about a fair scenario that will balance a pharmaceutical company's ability to develop a drug without rushing, but the generic drugs need to enter the market and compete.
Mr. Elliot.
On May 31st, 2016. See this statement in context.